Hermann, Robert http://orcid.org/0000-0002-1326-5943
Krajcsi, Peter
Fluck, Markus
Seithel-Keuth, Annick
Bytyqi, Afrim
Galazka, Andrew
Munafo, Alain
Funding for this research was provided by:
merck kgaa (CrossRef Funder ID: 10.13039/100009945)
Article History
Accepted: 7 November 2021
First Online: 11 December 2021
Declarations
:
: RH served as an external clinical pharmacology expert advisor for various aspects in the clinical development of cladribine, and received financial support for research, consulting, and training services from Merck Healthcare KGaA, Darmstadt, Germany. PK served as an external pharmacology expert advisor for in vitro transporter studies. He is a co-founder of Habilitas Kft, which received financial support for generation of an Internal Transporter Report from Merck Healthcare KGaA Darmstadt, Germany. He was also an employee of Solvo Biotechnology, Budapest, Hungary, outside this advisory work. ASK, MF, and AB are employees of Merck Healthcare KGaA Darmstadt, Germany. AG was an employee of Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA at the time of the study, and is currently a consultant to Merck Healthcare KGaA, Darmstadt, Germany. AM was at the time of preparation of this manuscript, an employee of the Merck Institute of Pharmacometrics, Lausanne, Switzerland, an affiliate of Merck KGaA.
: Not applicable.
: Not applicable.
: Not applicable.
: Any requests for data by qualified scientific and medical researchers for legitimate research purposes will be subject to Merck KGaA’s Data Sharing Policy. All requests should be submitted in writing to Merck KGaA’s data sharing portal: ExternalRef removed. When Merck KGaA has a co-research, co-development, or co-marketing or co-promotion agreement, or when the product has been out-licensed, the responsibility for disclosure might be dependent on the agreement between parties. Under these circumstances, Merck KGaA will endeavor to gain agreement to share data in response to requests.
: Not applicable.
: Not applicable.